92 results
Page 2 of 5
8-K
EX-10.1
ugkuvyr
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
luem84 34w
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
0u2h9g4sghykmfual
16 Feb 21
Entry into a Material Definitive Agreement
7:10am
8-K
EX-10.1
0nn 0m33p
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
zpsu1f4znw86 7qmmu26
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-10.3
7mnsebd
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.2
v175 6nbk
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
5jntd102e23ojpypti
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
htvlz cqglnhh0
13 Jan 20
Other Events
8:06am
8-K
EX-10.4
rs78w9lg7c
9 Jan 20
Aravive Announces Management Changes
4:59pm